A randomized, double-blind, placebo-controlled Phase IIa clinical study to evaluate the safety and efficacy of GST-HG131 tablets in patients with chronic hepatitis B
Able to sign the informed consent form，and fully understand the test content, process and possible adverse reactions；
Males and females aged 35-65 ,able to complete research in accordance with test plan requirements;
Participants who have no childbearing plan in next year,and must agree to voluntarily use the contraceptive methods specified in the protocol from screening to 6 months after the last dose of the study；
The weight of male patients shall not be less than 50 kg, and the weight of female patients is not less than 45 kg. Body mass index (BMI = weight (kg)/height 2 (m2)) in the range of 18.0~35.0 kg/m2；
Participants with a history of allergy to the any ingredient or excipients of the drug under study；
Patients who cannot tolerate venous blood collection and have a history of needle fainting or blood fainting；
Patients with major trauma or major surgery within 3 months before screening; or plan to have surgery during the study；
Blood donation or blood loss ≥400 mL within 3 months prior to screening, or received blood transfusion; or blood donation or blood loss ≥200 mL within 1 month prior to screening；
Parallel
GST-HG131
DrugGST-HG131 will be administered.
Placebo to match GST-HG131
DrugPlacebo to match GST-HG131 will be administered.
Change from Baseline in HBsAg levels
Change from Baseline in HBsAg levels
Number of participants with adverse events (AEs), serious adverse events (SAEs), and withdrawals due to AEs
Number of participants with adverse events (AEs), serious adverse events (SAEs), and withdrawals due to AEs
Click on the lead sponsor to view all of their trials.
